虽然默克研究显示克拉屈滨会降低复发率，邓斯特称真正的问题是该药是否会减缓该疾病的进程。

Though Merck's study showed that cladribine reduced the relapse rate, Dunster said the real question was whether the drug slowed the disease's progression.

youdao

默克在其记者发布会上称，在今年晚些时候，将在美国和欧洲提交克拉屈滨的注册申请。

In their press statement, Merck said they will submit cladribine for registration in the U. S. and Europe later this year.

youdao

默克在一次记者发布会中称，比安慰剂组相比，服用克拉屈滨(cladribine)片会使患者的复发率降低约60%。

In a press statement, Merck said that patients taking cladribine tablets had a nearly 60 percent lower relapse rate than those on placebo pills.

youdao

默克在一次记者发布会中称，比安慰剂组相比，服用克拉屈滨(cladribine)片会使患者的复发率降低约60%。

In a press statement, Merck said that patients taking cladribine tablets had a nearly 60 percent lower relapse rate than those on placebo pills.

youdao